Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Thromboprophylaxis in lower limb immobilisation after injury (TiLLI).

Horner D, Goodacre S, Pandor A, Nokes T, Keenan J, Hunt B, Davis S, Stevens JW, Hogg K.

Emerg Med J. 2019 Nov 6. pii: emermed-2019-208944. doi: 10.1136/emermed-2019-208944. [Epub ahead of print]

2.

Pharmacological thromboprophylaxis to prevent venous thromboembolism in patients with temporary lower limb immobilization after injury: systematic review and network meta-analysis.

Horner D, Stevens JW, Pandor A, Nokes T, Keenan J, de Wit K, Goodacre S.

J Thromb Haemost. 2019 Oct 26. doi: 10.1111/jth.14666. [Epub ahead of print]

PMID:
31654551
3.

Delphi consensus reached to produce a decision tool for SelecTing Approaches for Rapid Reviews (STARR).

Pandor A, Kaltenthaler E, Martyn-St James M, Wong R, Cooper K, Dimairo M, O'Cathain A, Campbell F, Booth A.

J Clin Epidemiol. 2019 Oct;114:22-29. doi: 10.1016/j.jclinepi.2019.06.005. Epub 2019 Jun 8.

PMID:
31185276
4.

Decision-analysis modelling of the effects of thromboprophylaxis for people with lower limb immobilisation for injury.

Davis S, Goodacre S, Pandor A, Horner D, Stevens JW, de Wit K, Hunt BJ.

Br J Haematol. 2019 Jul;186(1):166-168. doi: 10.1111/bjh.15748. Epub 2019 Jan 29. No abstract available.

PMID:
30697707
5.

Individual risk factors predictive of venous thromboembolism in patients with temporary lower limb immobilization due to injury: a systematic review.

Horner D, Pandor A, Goodacre S, Clowes M, Hunt BJ.

J Thromb Haemost. 2019 Feb;17(2):329-344. doi: 10.1111/jth.14367. Epub 2019 Feb 7.

6.

Assessing prognosis and prediction of treatment response in early rheumatoid arthritis: systematic reviews.

Archer R, Hock E, Hamilton J, Stevens J, Essat M, Poku E, Clowes M, Pandor A, Stevenson M.

Health Technol Assess. 2018 Nov;22(66):1-294. doi: 10.3310/hta22660.

7.

EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties.

Dickson R, Boland A, Duarte R, Kotas E, Woolacott N, Hodgson R, Riemsma R, Grimm S, Ramaekers B, Joore M, Büyükkaramikli N, Kaltenthaler E, Stevenson M, Pandor A, Edwards S, Hoyle M, Shepherd J, Armoiry X, Brazzelli M.

Appl Health Econ Health Policy. 2018 Aug;16(4):429-432. doi: 10.1007/s40258-018-0393-7. No abstract available.

8.

Obinutuzumab with Bendamustine for Treating Follicular Lymphoma Refractory to Rituximab: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Rafia R, Pandor A, Davis S, Stevens JW, Harnan S, Clowes M, Sorour Y, Cutting R.

Pharmacoeconomics. 2018 Oct;36(10):1143-1151. doi: 10.1007/s40273-018-0645-2. Review.

9.

Ponatinib for Treating Acute Lymphoblastic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Stevenson M, Pandor A, Hamilton J, Stevens J, Rowntree C, Martyn-St James M, Rawdin A, Wong R.

Pharmacoeconomics. 2018 Jul;36(7):759-768. doi: 10.1007/s40273-018-0624-7. Review.

10.

Ponatinib for Treating Chronic Myeloid Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Pandor A, Stevenson M, Stevens J, James MM, Hamilton J, Byrne J, Rudin C, Rawdin A, Wong R.

Pharmacoeconomics. 2018 Aug;36(8):903-915. doi: 10.1007/s40273-018-0627-4. Review.

11.

Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Squires H, Pandor A, Thokala P, Stevens JW, Kaltenthaler E, Clowes M, Coleman R, Wyld L.

Pharmacoeconomics. 2018 Jan;36(1):29-38. doi: 10.1007/s40273-017-0556-7. Review.

12.

GENE EXPRESSION PROFILING AND EXPANDED IMMUNOHISTOCHEMISTRY TESTS TO GUIDE SELECTION OF CHEMOTHERAPY REGIMENS IN BREAST CANCER MANAGEMENT: A SYSTEMATIC REVIEW.

Scope A, Essat M, Pandor A, Rafia R, Ward SE, Wyld L, Cross S, Woods HB.

Int J Technol Assess Health Care. 2017 Jan;33(1):32-45. doi: 10.1017/S0266462317000034. Epub 2017 May 10. Review.

13.

Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Kearns B, Pandor A, Stevenson M, Hamilton J, Chambers D, Clowes M, Graham J, Kumar MS.

Pharmacoeconomics. 2017 Apr;35(4):415-424. doi: 10.1007/s40273-016-0457-1. Review.

14.

The use of rapid review methods in health technology assessments: 3 case studies.

Kaltenthaler E, Cooper K, Pandor A, Martyn-St James M, Chatters R, Wong R.

BMC Med Res Methodol. 2016 Aug 26;16(1):108. doi: 10.1186/s12874-016-0216-1.

15.

Sepsis: the LightCycler SeptiFast Test MGRADE®, SepsiTest™ and IRIDICA BAC BSI assay for rapidly identifying bloodstream bacteria and fungi - a systematic review and economic evaluation.

Stevenson M, Pandor A, Martyn-St James M, Rafia R, Uttley L, Stevens J, Sanderson J, Wong R, Perkins GD, McMullan R, Dark P.

Health Technol Assess. 2016 Jun;20(46):1-246. doi: 10.3310/hta20460. Review.

16.
17.

Pre-hospital non-invasive ventilation for acute respiratory failure: a systematic review and cost-effectiveness evaluation.

Pandor A, Thokala P, Goodacre S, Poku E, Stevens JW, Ren S, Cantrell A, Perkins GD, Ward M, Penn-Ashman J.

Health Technol Assess. 2015 Jun;19(42):v-vi, 1-102. doi: 10.3310/hta19420. Review.

18.

Sexual health risk reduction interventions for people with severe mental illness: a systematic review.

Pandor A, Kaltenthaler E, Higgins A, Lorimer K, Smith S, Wylie K, Wong R.

BMC Public Health. 2015 Feb 12;15:138. doi: 10.1186/s12889-015-1448-4. Review.

19.

Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Stevenson M, Pandor A, Stevens JW, Rawdin A, Rice P, Thompson J, Morgan MY.

Pharmacoeconomics. 2015 Aug;33(8):833-47. doi: 10.1007/s40273-015-0272-0. Review.

21.

Prehospital noninvasive ventilation for acute respiratory failure: systematic review, network meta-analysis, and individual patient data meta-analysis.

Goodacre S, Stevens JW, Pandor A, Poku E, Ren S, Cantrell A, Bounes V, Mas A, Payen D, Petrie D, Roessler MS, Weitz G, Ducros L, Plaisance P.

Acad Emerg Med. 2014 Sep;21(9):960-70. doi: 10.1111/acem.12466. Review.

22.

The safety of intravitreal bevacizumab monotherapy in adult ophthalmic conditions: systematic review.

Poku E, Rathbone J, Wong R, Everson-Hock E, Essat M, Pandor A, Wailoo A.

BMJ Open. 2014 Jul 17;4(7):e005244. doi: 10.1136/bmjopen-2014-005244. Review.

23.

The effectiveness of sexual health interventions for people with severe mental illness: a systematic review.

Kaltenthaler E, Pandor A, Wong R.

Health Technol Assess. 2014 Jan;18(1):1-74. doi: 10.3310/hta18010. Review.

24.

Assessing the cost-effectiveness of type 1 diabetes interventions: the Sheffield type 1 diabetes policy model.

Thokala P, Kruger J, Brennan A, Basarir H, Duenas A, Pandor A, Gillett M, Elliott J, Heller S.

Diabet Med. 2014 Apr;31(4):477-86. doi: 10.1111/dme.12371. Epub 2014 Feb 5.

PMID:
24299192
25.

Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.

Ward S, Scope A, Rafia R, Pandor A, Harnan S, Evans P, Wyld L.

Health Technol Assess. 2013 Oct;17(44):1-302. doi: 10.3310/hta17440. Review.

26.

Telemonitoring after discharge from hospital with heart failure: cost-effectiveness modelling of alternative service designs.

Thokala P, Baalbaki H, Brennan A, Pandor A, Stevens JW, Gomersall T, Wang J, Bakhai A, Al-Mohammad A, Cleland J, Cowie MR, Wong R.

BMJ Open. 2013 Sep 18;3(9):e003250. doi: 10.1136/bmjopen-2013-003250.

27.

The cost-effectiveness of diagnostic management strategies for children with minor head injury.

Holmes MW, Goodacre S, Stevenson MD, Pandor A, Pickering A.

Arch Dis Child. 2013 Dec;98(12):939-44. doi: 10.1136/archdischild-2012-302820. Epub 2013 Aug 22.

PMID:
23968775
28.

Home telemonitoring or structured telephone support programmes after recent discharge in patients with heart failure: systematic review and economic evaluation.

Pandor A, Thokala P, Gomersall T, Baalbaki H, Stevens JW, Wang J, Wong R, Brennan A, Fitzgerald P.

Health Technol Assess. 2013 Aug;17(32):1-207, v-vi. doi: 10.3310/hta17320. Review.

29.

Remote monitoring after recent hospital discharge in patients with heart failure: a systematic review and network meta-analysis.

Pandor A, Gomersall T, Stevens JW, Wang J, Al-Mohammad A, Bakhai A, Cleland JG, Cowie MR, Wong R.

Heart. 2013 Dec;99(23):1717-26. doi: 10.1136/heartjnl-2013-303811. Epub 2013 May 16. Review.

PMID:
23680885
30.

Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal.

Whyte S, Pandor A, Stevenson M.

Pharmacoeconomics. 2012 Dec 1;30(12):1119-32. doi: 10.2165/11597210-000000000-00000. Review.

PMID:
23058097
31.

The cost-effectiveness of diagnostic management strategies for adults with minor head injury.

Holmes MW, Goodacre S, Stevenson MD, Pandor A, Pickering A.

Injury. 2012 Sep;43(9):1423-31. doi: 10.1016/j.injury.2011.07.017. Epub 2011 Aug 10.

PMID:
21835403
32.

Clinical decision rules for adults with minor head injury: a systematic review.

Harnan SE, Pickering A, Pandor A, Goodacre SW.

J Trauma. 2011 Jul;71(1):245-51. doi: 10.1097/TA.0b013e31820d090f. Review.

PMID:
21818031
33.

Diagnostic management strategies for adults and children with minor head injury: a systematic review and an economic evaluation.

Pandor A, Goodacre S, Harnan S, Holmes M, Pickering A, Fitzgerald P, Rees A, Stevenson M.

Health Technol Assess. 2011 Aug;15(27):1-202. doi: 10.3310/hta15270. Review.

34.

Diagnostic accuracy of clinical characteristics for identifying CT abnormality after minor brain injury: a systematic review and meta-analysis.

Pandor A, Harnan S, Goodacre S, Pickering A, Fitzgerald P, Rees A.

J Neurotrauma. 2012 Mar 20;29(5):707-18. doi: 10.1089/neu.2011.1967. Epub 2011 Oct 26. Review.

PMID:
21806474
35.

Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?

Ara R, Pandor A, Stevens J, Rafia R, Ward SE, Rees A, Durrington PN, Reynolds TM, Wierzbicki AS, Stevenson M.

Eur J Prev Cardiol. 2012 Jun;19(3):474-83. doi: 10.1177/1741826711406616. Epub 2011 Apr 1.

PMID:
21460076
36.

Clinical decision rules for children with minor head injury: a systematic review.

Pickering A, Harnan S, Fitzgerald P, Pandor A, Goodacre S.

Arch Dis Child. 2011 May;96(5):414-21. doi: 10.1136/adc.2010.202820. Epub 2011 Feb 10. Review.

PMID:
21310894
37.

Febuxostat for the management of hyperuricaemia in patients with gout: a NICE single technology appraisal.

Stevenson M, Pandor A.

Pharmacoeconomics. 2011 Feb;29(2):133-40. doi: 10.2165/11535770-000000000-00000. Review.

PMID:
21155617
38.

Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer.

Whyte S, Pandor A, Stevenson M, Rees A.

Health Technol Assess. 2010 Oct;14(Suppl. 2):47-53. doi: 10.3310/hta14suppl2/07. Review.

39.

Cell-specific differences in the processing of the R14W CAIV mutant associated with retinitis pigmentosa 17.

Pandor A, Ramesar R, Prince S.

J Cell Biochem. 2010 Oct 15;111(3):735-41. doi: 10.1002/jcb.22759.

PMID:
20626030
40.

Management of isolated minor head injury in the UK.

Goodacre SW, Pandor A, Pickering A.

Emerg Med J. 2010 Nov;27(11):856-9. doi: 10.1136/emj.2009.086389. Epub 2010 Jun 3.

PMID:
20522436
41.

Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal.

Stevenson M, Pandor A.

Health Technol Assess. 2009 Oct;13 Suppl 3:37-42. doi: 10.3310/hta13suppl3/06. Review.

42.

Health burden of co-morbid asthma and allergic rhinitis in West Indian children.

Pinto Pereira LM, Jackman J, Figaro N, Babootee N, Cudjoe G, Farrell S, Francis-Regis C, Garcia Henry K, Pandor A, Walters T, Bekele I.

Allergol Immunopathol (Madr). 2010 May-Jun;38(3):129-34. doi: 10.1016/j.aller.2009.09.002. Epub 2009 Dec 22.

PMID:
20031294
43.

Are intensive lipid-lowering regimens an optimal economic strategy in patients with ACS? An acute and chronic perspective.

Ara R, Rafia R, Ward SE, Wierzbicki AS, Reynolds TM, Rees A, Pandor A.

Expert Rev Pharmacoecon Outcomes Res. 2009 Oct;9(5):423-33. doi: 10.1586/erp.09.42. Review.

PMID:
19817526
44.

Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation.

Ara R, Pandor A, Stevens J, Rees A, Rafia R.

Health Technol Assess. 2009 Jul;13(34):1-74, 75-118. doi: 10.3310/hta13340. Review.

45.

Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: a Markov model.

Ara R, Pandor A, Tumur I, Paisley S, Duenas A, Williams R, Rees A, Wilkinson A, Durrington P, Chilcott J.

Am J Cardiovasc Drugs. 2008;8(6):419-27. doi: 10.2165/0129784-200808060-00005.

PMID:
19159125
46.

Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials.

Pandor A, Ara RM, Tumur I, Wilkinson AJ, Paisley S, Duenas A, Durrington PN, Chilcott J.

J Intern Med. 2009 May;265(5):568-80. doi: 10.1111/j.1365-2796.2008.02062.x. Epub 2008 Dec 28. Review.

47.

Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries.

Ara R, Pandor A, Tumur I, Paisley S, Duenas A, Williams R, Wilkinson A, Durrington P, Chilcott J.

Clin Ther. 2008 Aug;30(8):1508-23. doi: 10.1016/j.clinthera.2008.08.002.

PMID:
18803993
48.

Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation.

Ara R, Tumur I, Pandor A, Duenas A, Williams R, Wilkinson A, Paisley S, Chilcott J.

Health Technol Assess. 2008 May;12(21):iii, xi-xiii, 1-212. Review.

49.

A systematic review and economic evaluation of statins for the prevention of coronary events.

Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N.

Health Technol Assess. 2007 Apr;11(14):1-160, iii-iv. Review.

50.

The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.

Pandor A, Eggington S, Paisley S, Tappenden P, Sutcliffe P.

Health Technol Assess. 2006 Nov;10(41):iii-iv, xi-xiv, 1-185. Review.

Supplemental Content

Loading ...
Support Center